DK151884C - Analogifremgangsmaade til fremstilling af 3-(1-imidazolylalkyl)indolderivater eller farmaceutisk acceptable syreadditionssalte deraf - Google Patents

Analogifremgangsmaade til fremstilling af 3-(1-imidazolylalkyl)indolderivater eller farmaceutisk acceptable syreadditionssalte deraf

Info

Publication number
DK151884C
DK151884C DK042580A DK42580A DK151884C DK 151884 C DK151884 C DK 151884C DK 042580 A DK042580 A DK 042580A DK 42580 A DK42580 A DK 42580A DK 151884 C DK151884 C DK 151884C
Authority
DK
Denmark
Prior art keywords
imidazolylalkyl
incidental
analogue
preparation
acid addition
Prior art date
Application number
DK042580A
Other languages
Danish (da)
English (en)
Other versions
DK42580A (da
DK151884B (da
Inventor
Peter Edward Cross
Roger Peter Dickinson
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of DK42580A publication Critical patent/DK42580A/da
Publication of DK151884B publication Critical patent/DK151884B/da
Application granted granted Critical
Publication of DK151884C publication Critical patent/DK151884C/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK042580A 1979-03-07 1980-01-31 Analogifremgangsmaade til fremstilling af 3-(1-imidazolylalkyl)indolderivater eller farmaceutisk acceptable syreadditionssalte deraf DK151884C (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB7908123 1979-03-07
GB7908123 1979-03-07

Publications (3)

Publication Number Publication Date
DK42580A DK42580A (da) 1980-09-08
DK151884B DK151884B (da) 1988-01-11
DK151884C true DK151884C (da) 1988-06-13

Family

ID=10503707

Family Applications (1)

Application Number Title Priority Date Filing Date
DK042580A DK151884C (da) 1979-03-07 1980-01-31 Analogifremgangsmaade til fremstilling af 3-(1-imidazolylalkyl)indolderivater eller farmaceutisk acceptable syreadditionssalte deraf

Country Status (36)

Country Link
US (1) US4273782A (nl)
JP (1) JPS55133380A (nl)
KR (1) KR850000760B1 (nl)
AR (1) AR227015A1 (nl)
AT (1) AT375366B (nl)
AU (1) AU516957B2 (nl)
BE (1) BE882113A (nl)
CA (1) CA1120479A (nl)
CH (1) CH649546A5 (nl)
CS (1) CS253702B2 (nl)
DD (1) DD149525A5 (nl)
DE (1) DE3008632A1 (nl)
DK (1) DK151884C (nl)
ES (2) ES8104278A1 (nl)
FI (1) FI66860C (nl)
FR (1) FR2450832A1 (nl)
GR (1) GR67237B (nl)
HK (1) HK89884A (nl)
HU (1) HU184727B (nl)
IE (1) IE49542B1 (nl)
IL (1) IL59524A (nl)
IT (1) IT1218420B (nl)
KE (1) KE3467A (nl)
LU (1) LU82224A1 (nl)
MY (1) MY8500285A (nl)
NL (1) NL182959C (nl)
NO (1) NO152217C (nl)
NZ (1) NZ193052A (nl)
PH (1) PH15198A (nl)
PL (1) PL128296B1 (nl)
PT (1) PT70914A (nl)
SE (1) SE440778B (nl)
SG (1) SG67284G (nl)
SU (1) SU1277894A3 (nl)
YU (1) YU41911B (nl)
ZA (1) ZA801328B (nl)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4414159A (en) * 1980-09-26 1983-11-08 E. I. Du Pont De Nemours & Co. Vinyl ether monomers and polymers therefrom
US4444775A (en) * 1981-06-22 1984-04-24 Ciba-Geigy Corporation Substituted imidazo[1,5-A]pyridines
KR840000529A (ko) * 1981-07-07 1984-02-25 콘스탄틴 루이스 클레멘트 인돌 유도체의 제조방법
ZA825413B (en) * 1981-08-26 1983-06-29 Pfizer Thromboxane synthetase inhibitors, processes for their production, and pharmaceutical compositions comprising them
US4478842A (en) * 1981-11-19 1984-10-23 Ciba-Geigy Corporation N-Substituted-2-pyridylindoles
US4460777A (en) * 1981-11-19 1984-07-17 Ciba-Geigy Corporation N-Substituted-2-pyridylindoles
US4436746A (en) 1982-09-30 1984-03-13 Ciba-Geigy Corporation Thromboxane synthetase inhibitory N-substituted-2-(1-imidazolyl)indoles
US4539410A (en) * 1982-09-30 1985-09-03 Ciba-Geigy Corporation N-Substituted-2-(1-imidazolyl)indoles
AT376436B (de) * 1982-11-05 1984-11-26 Laevosan Gmbh & Co Kg Verfahren zur herstellung neuer thiophen-2carbons[urederivate und pharmazeutisch vertraeglicher saeure- oder basenadditionssalze davon
US4511573A (en) * 1983-05-17 1985-04-16 Ciba-Geigy Corporation 3-Substituted-2-(heteroaryl) indoles
DE3786030T2 (de) 1986-03-27 1993-12-02 Merck Frosst Canada Inc Tetrahydrocarbazole Ester.
JPH0832679B2 (ja) * 1986-09-05 1996-03-29 理化学研究所 Ｎ―フタルイシド誘導体及びその製造法
GR871809B (en) * 1986-11-28 1988-03-07 Glaxo Group Ltd Process for the preparation of tricyclic ketones
KR920700210A (ko) * 1989-03-31 1992-02-19 기따미 가즈히꼬 신규 이미다졸 유도체, 그의 제법 및 그의 의약용도
DE4023215A1 (de) * 1990-07-21 1992-01-23 Hoechst Ag Substituierte azole, verfahren zu deren herstellung, sie enthaltende mittel und deren verwendung
KR930702334A (ko) * 1990-09-13 1993-09-08 데이비드 로버트 5 하이드록시트립타민 수용체 길항제로서의 인돌우레아
US5162337A (en) * 1990-10-05 1992-11-10 Merck & Co., Inc. Animal growth promotion
US5120749A (en) * 1991-02-20 1992-06-09 Abbott Laboratories Platelet activating antagonists
SG44510A1 (en) * 1991-12-18 1997-12-19 Schering Corp Imidazolyl or imidazoylalkyl substituted with a four or five membered nitrogen containing heterocyclic ring
US5538973A (en) * 1992-03-27 1996-07-23 Kyoto Pharmaceutical Industries, Ltd. Imidazole derivative, pharmaceutical use thereof, and intermediate therefor
CA2109931A1 (en) * 1992-03-27 1993-10-14 Hiroshi Matsui Novel imidazole derivative, pharmaceutical use thereof, and intermediate therefor
JPH0632913U (ja) * 1992-09-18 1994-04-28 三洋電機株式会社 床暖房用パネル
OA11622A (en) * 1998-03-31 2004-09-16 Inst For Pharm Discovery Inc Substituted indolealkanoic acids.
BR0316583A (pt) * 2002-12-10 2005-10-04 Wyeth Corp Derivados de ácido acético 3-alquil e 3-arilalquil 1h-indol-1-il substituìdo como inibidores do inibidor-1 do ativador do plasminogênio (pai-1)
GB0324763D0 (en) 2003-10-23 2003-11-26 Oxagen Ltd Use of compounds in therapy
MX2007004525A (es) * 2004-10-12 2007-09-19 Decode Genetics Inc Sulfonamidas biciclicas peri-sustituidas para enfermedad de arteria oclusiva.
KR20080039982A (ko) * 2005-08-25 2008-05-07 쉐링 코포레이션 작용 선택적 알파2ｃ 아드레날린성 수용체 효능제로서의이미다졸 유도체
US7977359B2 (en) * 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
US8399666B2 (en) * 2005-11-04 2013-03-19 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
GB2431927B (en) * 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
US7579483B2 (en) * 2006-05-16 2009-08-25 Decode Genetics, Ehf. Process for preparing 7-(acryloyl)indoles
RU2458918C2 (ru) 2006-07-22 2012-08-20 Оксаген Лимитед Соединения, обладающие антагонистической активностью по отношению к crth2
TW200920369A (en) * 2007-10-26 2009-05-16 Amira Pharmaceuticals Inc 5-lipoxygenase activating protein (flap) inhibitor
EP2543368A1 (en) 2007-12-11 2013-01-09 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
RU2503672C2 (ru) 2008-01-18 2014-01-10 Оксаген Лимитед Соединения, обладающие активностью антагонистов crth2
US7750027B2 (en) * 2008-01-18 2010-07-06 Oxagen Limited Compounds having CRTH2 antagonist activity
WO2009093029A1 (en) * 2008-01-22 2009-07-30 Oxagen Limited Compounds having crth2 antagonist activity
EP2265581A1 (en) * 2008-01-22 2010-12-29 Oxagen Limited Compounds having crth2 antagonist activity
MX2010012814A (es) * 2008-05-23 2010-12-20 Amira Pharmaceuticals Inc Inhibidor de proteina activadora de 5-lipoxigenasa.
US8546431B2 (en) 2008-10-01 2013-10-01 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
CN103929961A (zh) * 2011-06-20 2014-07-16 美国阿尔茨海默病研究所公司 化合物及其治疗应用
GB201322273D0 (en) 2013-12-17 2014-01-29 Atopix Therapeutics Ltd Process
GB201407820D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
GB201407807D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
US11530186B2 (en) * 2018-03-29 2022-12-20 H. Lee Moffitt Cancer Center and Research Center Institute, Inc. Inhibitors for the β-catenin / T-cell factor protein-protein interaction

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL125443C (nl) * 1963-06-06
US3370063A (en) * 1964-10-05 1968-02-20 Mcneilab Inc Substituted dimethoxy indoles and method of making the same
US3621027A (en) * 1968-03-18 1971-11-16 Endo Lab 1-aminoalkyl-2,6-diaryl 4,5,6,7 tetrahydro-4-oxindales
US3931229A (en) * 1973-08-23 1976-01-06 Warner-Lambert Company 3-Thiomethyl-2[2-(dialkylamino)ethyl]indoles
US4059583A (en) * 1975-11-13 1977-11-22 Mcneil Laboratories, Incorporated Substituted indoles
DK376078A (da) * 1977-08-26 1979-02-27 Wellcome Found Fremgangsmaade til fremstilling af amidazoler
US4140858A (en) * 1977-12-19 1979-02-20 Warner-Lambert Company 3-(1H-imidazol-1-ylmethyl)-2-(disubstitutedaminomethyl)indoles and a method for their production
EP0003901B1 (en) * 1978-02-24 1981-08-05 Pfizer Limited 3-(imidazol-1-ylalkyl)indoles as selective inhibitors of thromboxane synthetase,pharmaceutical compositions thereof, and methods for preparing them

Also Published As

Publication number Publication date
LU82224A1 (fr) 1980-06-06
NL8001351A (nl) 1980-09-09
PL222470A1 (nl) 1980-12-01
SG67284G (en) 1985-03-15
FI800672A (fi) 1980-09-08
YU61480A (en) 1983-12-31
NO152217C (no) 1985-08-21
ES489220A0 (es) 1981-04-01
AU5623180A (en) 1980-09-11
FR2450832A1 (fr) 1980-10-03
CA1120479A (en) 1982-03-23
DK42580A (da) 1980-09-08
ATA125780A (de) 1983-12-15
CH649546A5 (de) 1985-05-31
DD149525A5 (de) 1981-07-15
DE3008632C2 (nl) 1988-02-25
FI66860B (fi) 1984-08-31
ES8205789A1 (es) 1982-08-01
IE800453L (en) 1980-09-07
AR227015A1 (es) 1982-09-15
HU184727B (en) 1984-10-29
DK151884B (da) 1988-01-11
MY8500285A (en) 1985-12-31
NO800650L (no) 1980-09-08
KR830001928A (ko) 1983-05-19
JPS55133380A (en) 1980-10-17
FR2450832B1 (nl) 1983-04-22
NO152217B (no) 1985-05-13
KR850000760B1 (ko) 1985-05-25
IE49542B1 (en) 1985-10-30
IL59524A (en) 1982-11-30
HK89884A (en) 1984-11-23
GR67237B (nl) 1981-06-25
AT375366B (de) 1984-07-25
PL128296B1 (en) 1984-01-31
IL59524A0 (en) 1980-06-30
NL182959C (nl) 1988-06-16
YU41911B (en) 1988-02-29
DE3008632A1 (de) 1980-10-16
BE882113A (fr) 1980-09-08
JPS6141513B2 (nl) 1986-09-16
NZ193052A (en) 1984-07-06
SE8001736L (sv) 1980-09-08
SU1277894A3 (ru) 1986-12-15
ES496889A0 (es) 1982-08-01
CS253702B2 (en) 1987-12-17
SE440778B (sv) 1985-08-19
KE3467A (en) 1984-11-09
AU516957B2 (en) 1981-07-02
PH15198A (en) 1982-09-17
IT1218420B (it) 1990-04-19
ZA801328B (en) 1981-03-25
PT70914A (en) 1980-04-01
ES8104278A1 (es) 1981-04-01
IT8020399A0 (it) 1980-03-06
US4273782A (en) 1981-06-16
FI66860C (fi) 1984-12-10

Similar Documents

Publication Publication Date Title
DK151884C (da) Analogifremgangsmaade til fremstilling af 3-(1-imidazolylalkyl)indolderivater eller farmaceutisk acceptable syreadditionssalte deraf
DK151623C (da) Analogifremgangsmaade til fremstilling af n-substituerede moranolinderivater eller farmaceutisk acceptable syreadditionssalte deraf
DK147362C (da) Analogifremgangsmaade til fremstilling af ergolen- eller ergolin-derivater eller syreadditionssalte deraf
DK151331C (da) Analogifremgangsmaade til fremstilling af 5-pyridinyl-2(1h)-pyridinon-forbindelser eller farmaceutisk acceptable syreadditionssalte deraf
DK149308C (da) Analogifremgangs-maade til fremstilling af trans-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamin-derivater eller farmaceutisk acceptablesyreadditionssalte deraf
DK162714C (da) Analogifremgangsmaade til fremstilling af glycinamidderivater eller syreadditionssalte deraf
DK149895C (da) Fremgangsmaade til fremstilling af alfa-aminoacylprolyl-ng-carboxy-argininaldehydderivater eller farmaceutisk acceptable syreadditionssalte deraf
DK164545C (da) Analogifremgangsmaade til fremstilling af sulfonylamino- eller sulfonylaminoalkylphenoxyalkylcarbonsyrederivater eller fysiologisk uskadelige salte deraf
DK149630C (da) Analogifremgangsmaade til fremstilling af tripeptidamider eller -estere eller fysiologisk acceptable syreadditionssalte deraf
DK151017C (da) Analogifremgangsmaade til fremstilling af substituerede n-(4-indolyl-piperidino-alkyl)-benzimidazoloner eller fysiologisk acceptable syreadditionssalte deraf
DK149569C (da) Analogifremgangsmaade til fremstilling af isoquinolineddikesyre-forbindelser eller farmaceutisk acceptable salte deraf
DK157862C (da) Analogifremgangsmaade til fremstilling af imidazolylphenylamidiner eller farmaceutisk acceptable syreadditionssalte deraf
DK154950C (da) Analogifremgangsmaade til fremstilling af 1-(benzazolylalkyl)-piperidinderivater eller de farmaceutisk acceptable syreadditionssalte deraf
DK158658C (da) Analogifremgangsmaade til fremstilling af 9-aminoalkylfluorener eller farmaceutisk acceptable salte deraf
DK142544C (da) Analogifremgangsmaade til fremstilling af 2-(n-propargyl-n-phenylamino)-imidazolin-(2)-derivater eller fysiologisk acceptable syreadditionssalte heraf
DK151805C (da) Analogifremgangsmaade til fremstilling af 20,21-di-nor-eburnameninderivater eller farmaceutisk acceptable additionssalte deraf
DK149841C (da) Analogifremgangsmaade til fremstilling af alfa-fluor-methyl-alfa-aminoalkansyrer eller farmaceutisk acceptable syreadditionssalte deraf
DK149077C (da) Analogifremgangsmaade til fremstilling af encephalin-analoge pentapeptidamidderivater eller farmaceutisk acceptable syreadditionssalte deraf
DK146066C (da) Analogifremgangsmaade til fremstilling af substituerede 2-phenylimino- imidazolidiner eller syreadditionssalte deraf
DK152427C (da) Analogifremgangsmaade til fremstilling af 4-thiomethylpyridinforbindelser eller farmaceutisk acceptable syreadditionssalte deraf
DK152208C (da) Analogifremgangsmaade til fremstilling af 2-phenylamino-phenyleddikesyreamider eller farmaceutisk acceptable salte deraf
DK165005C (da) Analogifremgangsmaade til fremstilling af 4,5-dihydro-4-oxofuran-2-carboxylsyrederivater eller terapeutisk acceptable salte deraf
DK144793C (da) Analogifremgangsmaade til fremstilling af dihydro- eller tetrahydroiminothiaziner eller farmaceutisk acceptable syreadditionssalte deraf
DK157023C (da) Analogifremgangsmaade til fremstilling af imidazodiazepiner eller farmaceutisk acceptable syreadditionssalte deraf
DK160874C (da) Analogifremgangsmaade til fremstilling af ergol-8-en- eller ergolinforbindelser eller farmaceutisk acceptable syreadditionssalte deraf